Sunitinib and other targeted therapies for renal cell carcinoma

Powles, T., Chowdhury, S., Jones, R. , Mantle, M., Nathan, P., Bex, A., Lim, L. and Hutson, T. (2011) Sunitinib and other targeted therapies for renal cell carcinoma. British Journal of Cancer, 104(5), pp. 741-745. (doi: 10.1038/sj.bjc.6606061)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1038/sj.bjc.6606061

Abstract

Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and an established toxicity profile. However, as further randomised studies report and as newer drugs become available this may change. In this review, we address our current understanding of targeted therapy in renal cancer. We also discuss areas in which our knowledge is incomplete, including the identification of correlative biomarkers and mechanisms of drug resistance. Finally, we will describe the major areas of clinical research that will report over the next few years.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Powles, T., Chowdhury, S., Jones, R., Mantle, M., Nathan, P., Bex, A., Lim, L., and Hutson, T.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:British Journal of Cancer
ISSN:0007-0920

University Staff: Request a correction | Enlighten Editors: Update this record